Table 2. (a) Change in body mass and composition and health-related quality of life and (b) resting energy expenditure dietary intake and C-reactive protein over the course of chemotherapy in patients with advanced NSCLC, metastatic breast cancer and metastatic melanoma.
|
Advanced NSCLC: 15 males, four
females
|
Metastatic melanoma: nine males, three
females
|
Metastatic breast cancer: 10 females
|
||||
|---|---|---|---|---|---|---|
| Prechemotherapy | Δ from Prechemotherapy | Prechemotherapy | Δ from Prechemotherapy | Prechemotherapy | Δ from Prechemotherapy | |
| (a) | ||||||
| Weight (kg) | 72.8 (17.9)a | 0.94 (−3,4.9)b | 81.0 (13.7) | 0.24 (−2.4, 2.9) | 73.6 (18.9) | −0.3 (−5.7,5.1) |
| FFM (kg) | 52.6 (11.6) | −1.1 (−3.1,0.9) | 56.2 (9.8) | 0.6 (−1.6, 2.9) | 45.7 (8.9) | −1.9 (−4.9,1.1) |
| Total fat (kg) | 20.1 (8.5) | 2.1 (−1.2,5.3) | 24.7 (6.6) | −0.6 (−3.4, 2.2) | 27.9 (10.7) | 1.5 (−1.2,4.4) |
| % Body fat | 26.9 (6.8) | 1.7 (−0.9, 4.3) | 30.4 (5.5) | 0.36 (−3.6, 2.9) | 37.3 (5.0) | 2.1 (0.8, 3.5)* |
| Mid arm muscle circumference (cm) | 25 (3.2) | 0.0 (−0.9,0.9) | 28.5 (2.4) | −1 (−2,−0.2)* | 28 (2.0) | −1 (−2.3−0.4) |
| Total body potassium (counts)c | 1115 (116) | 8.0 (−67–82) | 1252 (210) | −99 (−235,35) | 856 (189) | 65 (−54,186) |
| Tricep skin fold (mm) | 11.1 (4.2) | 1.0 (−1.7, 3.6) | 12.7 (4.6) | −0.2 (−3.4, 3) | 16.0 (11.0) | 1.8 (−0.3−4.0) |
| Bicep skinfold (mm) | 7.4 (3.5) | 0.4 (−2.5,3.3) | 8.9 (3.4) | −0.7 (−3.5,2.1) | 10.0 (7.0) | 0.7 (−3,5) |
| Subscapular skin fold (mm) | 18.0 (8.3) | 3.3 (−1.6–8.2) | 21.6 (8.0) | 1.4 (−3.5,6.3) | 29.0 (12.3) | 3.3 (−3.3,8.6) |
| Suprailiac skinfold (mm) | 15 (10) | 3.7 (−0.5–8.0) | 210.5 (9.0) | −2 (−9,5) | 30.0 (16.1) | 5.6 (−0.7,12.0) |
| Fact-G score | 86 (15) | −3 (−14,9) | 89 (20) | 0.8 (−7, 8) | 91 (14) | −8 (−3,12)* |
| (b) | ||||||
| REE (kJ) | 7250 (1807) | −334 (−874, 205) | 7217 (1380) | 66 (−418,548) | 5887 (1334) | 15 (−297,170) |
| REE (kJ kg−1) | 100 (19) | −5.9 (−8.8.34) | 89 (4.6) | 0 (−7,8) | 78 (6.7) | 0.4 (−10.5,10.5) |
| REE (kJ kg−1 FFM) | 138 (21) | −3 (−11,5.5) | 129 (11) | −0.8 (−12,10) | 129 (12) | 5 (−0.1,11) |
| Energy intake (kJ) | 10439 (3565) | 381 (−1209,1970) | 7246 (2004) | 600 (125,1076) | 7552 (1840) | 974(326,1230)* |
| Energy intake (kJ kg−1) | 154 (66) | 1.3 (−23,26) | 96 (25) | 30 (8,50) | 100 (3.1) | 10 (4,17)* |
| Protein intake (g) | 98.4 (33) | −3.5 (−17, 10) | 72.3 (15) | 22.5 (5.0,40.5) | 71.3 (23.4) | 7.3 (1.3,13)* |
| C-reactive protein (mg l−1) | 17.5 (5–182)d | −0.3 (−31,31) | 5 (5, 24) | 13.6 (−4.3, 31.6) | 6.5 (5,165) | 2.4 (−20, 25) |
a
Mean (s.d.)
b
Mean (95% confidence intervals).
c
NSCLC n=14; metastatic melanoma n=10; metastatic breast cancer n=8.
d
Median (range). FFM=fat-free mass; REE=resting energy expenditure.
*
Significant difference between prechemotherapy and post chemotherapy (P<0.05).
*
Significant difference between prechemotherapy and post chemotherapy (P<0.01).